This study presents intriguing findings on the synergistic effects of TLR1/2 ligands combined with proteasome inhibitors in multiple myeloma cells. I noticed that synergy scores above 6.7 are highlighted, which is promising. However, it made me wonder how these scores align with therapeutic relevance in clinical contexts. Are these thresholds based on established benchmarks in similar studies, or do they represent a novel evaluation for these combinations? Given the variability observed between cell lines like U266 and NCI-H929, were any sensitivity analyses performed to assess the robustness of the synergy scores under varying experimental conditions?
